Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)

Détails

ID Serval
serval:BIB_872E092C2090
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)
Périodique
Eur J Radiol
Auteur(s)
Mabille M., Vanel D., Albiter M., Le Cesne A., Bonvalot S., Le Pechoux C., Terrier P., Shapeero L. G., Dromain C.
ISSN-L
1872-7727 (Electronic)0720-048X (Linking)
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
69
Numéro
2
Pages
204-8
Langue
anglais
Notes
Mabille, MyleneVanel, DanielAlbiter, MarcelaLe Cesne, AxelBonvalot, SylvieLe Pechoux, CecileTerrier, PhilippeShapeero, Lorraine GDromain, ClarisseengClinical TrialIreland2008/12/03 09:00Eur J Radiol. 2009 Feb;69(2):204-8. doi: 10.1016/j.ejrad.2008.10.009. Epub 2008 Nov 28.
Résumé
PURPOSE: To define computed tomography (CT) criteria for evaluating the response of patients with gastrointestinal stromal tumors (GIST) who are receiving Imatinib (tyrosine-kinase inhibitor therapy). MATERIALS AND METHODS: This prospective CT study evaluated 107 consecutive patients with advanced metastatic GIST treated with Imatinib. RESULTS: Seventy patients had total or partial cystic-like transformation of hepatic and/or peritoneal metastases. These pseudocysts remained unchanged in size or stable in size on successive CT examinations (stable disease according to RECIST criteria). Forty-six patients developed metastases, 17 patients showed increasing parietal thickness and 29 patients with peripheral enhancing nodules. These CT changes represented local recurrence consistent with GIST resistance to Imatinib treatment. WHO or RECIST criteria did not provide a reliable evaluation of disease evolution or recurrence. Development of new enhancement of lesions (parietal thickness or nodule) was the only reliable criterion. CONCLUSION: The development of peripheral thickening or enhancing nodules within cystic-like metastatic lesions, even without any change in size, represented progressive GIST under Imatinib, growing in a short time and should alert the clinician for the possible need for a change in therapy.
Mots-clé
Adult, Aged, Aged, 80 and over, Antineoplastic Agents/administration & dosage, Benzamides, Female, Follow-Up Studies, *Gastrointestinal Stromal Tumors/drug therapy/radiography/secondary, Humans, Imatinib Mesylate, *Liver Neoplasms/drug therapy/radiography/secondary, Male, Middle Aged, *Peritoneal Neoplasms/drug therapy/radiography/secondary, Piperazines/*therapeutic use, Pyrimidines/*therapeutic use, Reproducibility of Results, Sensitivity and Specificity, Tomography, X-Ray Computed/*methods, Treatment Outcome
Création de la notice
16/09/2016 10:13
Dernière modification de la notice
20/08/2019 14:46
Données d'usage